drugset / Trial / NCT04716569

Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

NCT04716569

Phase 2/3 Unknown 150 enrolled South Valley University
RandomizedParallel-groupOpen-labelTreatment

Summary

Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

Timeline

Start
2021-01-20
Primary completion
2021-02-20
Completion
2021-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule Intranasal

Indications